Current aspects of diagnosis and treatment of patients with neuroendocrine tumors

Abstract

The article presents modern possibilities and existing problematic aspects of the choice of therapeutic and diagnostic tactics in patients with neuroendocrine tumors of the gastrointestinal tract and pancreas are presented. The asymptomatic course of neuroendocrine tumors of the gastrointestinal tract and pancreas was established in 18.5% and 24.6% of cases, respectively. Carcinoid syndrome was detected in 12.9%. The sensitivity rates of chromogranin A and neuron-specific enolase in the diagnosis of tumors were 54% and 13%, respectively. The levels of cancer-embryonic antigen in G-1/G-2 and G-3 tumors were < 5 ng/ml and 8.9 ng/ml, respectively (p < 0.001). A pathognomonic sign of neuroendocrine tumors of the small intestine is a mesentery tumor conglomerate, and the sensitivity rates of computed tomography and positron emission tomography with 68Ga to detect this sign were 92.3% and 92.9%, respectively (p > 0.05). The computed tomographic density of neuroendocrine pancreatic tumors G-1/G-2 in the arterial phase was 112.1 ± 40.2 HU and that of G-3 tumors was 54.0 ± 10.4 HU (p = 0.025). Surgical treatment was performed in 259 (79.7%) patients. Postoperative complications that developed in localized and locally distributed neuroendocrine tumors of the gastrointestinal tract and of the pancreas were found in 3.5% and 8.8%, and in 58.1% and 40% of the cases, respectively, and those of generalized tumors were noted in 20%. The tumor-specific 5-year survival rates of patients with localized neuroendocrine tumors of the gastrointestinal tract and pancreas were 92.5% and 94.4%, those with locally distributed tumors had 66.8% and 77.8%, and those with generalized tumors had 51.8% and 47.1%, respectively. In patients with generalized tumors, the 5-year survival rates after cytoreduction and removal of the primary tumor were 88.2% and 64.6%, respectively (p = 0.097), and the rate after drug therapy was 28.8% (p < 0.001). The prognosis of the 5-year survival of patients is determined by the degree of malignancy and tumor localization, treatment method, and patient age. In general, neuroendocrine tumors are a heterogeneous group of neoplasms that require a multidisciplinary approach to diagnosis and choice of therapeutic strategies.

Keywords

neuroendocrine tumor / gastrointestinal tract / pancreas / carcinoid syndrome / diagnostics / surgical treatment / disease prognosis

References

[1] Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–597. DOI: 10.1002/cncr.29099

[2] Hallet J., Law C.H., Cukier M., et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes // Cancer. 2015. Vol. 121, No. 4. P. 589–597. DOI: 10.1002/cncr.29099

[3] Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. DOI: 10.1001/jamaoncol.2017.0589

[4] Dasari A., Shen C., Halperin D., et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States // JAMA Oncol. 2017. Vol. 3, No. 10. P. 1335–1342. DOI: 10.1001/jamaoncol.2017.0589

[5] Gatta G, Trama A, Capocaccia R, et al. RARECARENet Working Group. Epidemiology of rare cancers and inequalities in oncologic outcomes. Eur J Surg Oncol. 2019;45(1):3–11. DOI: 10.1016/j.ejso.2017.08.018

[6] Gatta G., Trama A., Capocaccia R., et al. RARECARENet Working Group. Epidemiology of rare cancers and inequalities in oncologic outcomes // Eur J Surg Oncol. 2019. Vol. 45, No. 1. P. 3–11. DOI: 10.1016/j.ejso.2017.08.018

[7] Kaprin AD, Starinskij VV, Petrova GV. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2018 godu. M.: MNIOI im. PA. Gercena — filial FGBU "NMIC radiologii" Minzdrava Rossii. 2019; p. 236. (In Russ.).

[8] Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.

[9] Andreasi V, Partelli S, Muffatti F, et al. Update on gastroenteropancreatic neuroendocrine tumors. Dig Liver Dis. 2021;53(2):171–182. DOI: 10.1016/j.dld.2020.08.031

[10] Andreasi V., Partelli S., Muffatti F., et al. Update on gastroenteropancreatic neuroendocrine tumors // Dig Liver Dis. 2021. Vol. 53, No. 2. P. 171–182. DOI: 10.1016/j.dld.2020.08.031

[11] Majstrenko NA, Romashchenko PN, Lysanyuk MV. Diagnosis and surgical treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. Annals of HPB Surgery. 2016;21(1):13–20. (In Russ.). DOI: 10.16931/1995-5464.2016113-20

[12] Майстренко Н.А., Ромащенко П.Н., Лысанюк М.В. Диагностика и лечение нейроэндокринных опухолей поджелудочной железы и желудочно-кишечного тракта // Анналы хирургической гепатологии. 2016. Т. 21, № 1. С. 13–20. DOI: 10.16931/1995-5464.2016113-20

[13] Verbeek WH, Korse CM, Tesselaar ME. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur J Endocrinol. 2016;174(1):R1–R7. DOI: 10.1530/EJE-14-0971

[14] Verbeek W.H., Korse C.M., Tesselaar M.E. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers // Eur J Endocrinol. 2016. Vol. 174, No. 1. P. R1–R7. DOI: 10.1530/EJE-14-0971

[15] Capdevila J, Bodei L, Davies P, et al. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. Neuroendocrinology. 2019;108(1):18–25. DOI: 10.1159/000493319

[16] Capdevila J., Bodei L., Davies P., et al. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms // Neuroendocrinology. 2019. Vol. 108, No. 1. P. 18–25. DOI: 10.1159/000493319

[17] Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41(2):371–403. DOI: 10.1210/endrev/bnz004

[18] Hofland J., Kaltsas G., de Herder W.W. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms // Endocr Rev. 2020. Vol. 41, No. 2. P. 371–403. DOI: 10.1210/endrev/bnz004

[19] Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9): 435–446. DOI: 10.1016/S1470-2045(15)00186-2

[20] Oberg K., Modlin I.M., De Herder W., et al. Consensus on biomarkers for neuroendocrine tumour disease // Lancet Oncol. 2015. Vol. 16, No. 9. P. 435–446. DOI: 10.1016/S1470-2045(15)00186-2

[21] Yazici C, Boulay BR. Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors. World J Gastroenterol. 2017;23(27):4847–4855. DOI: 10.3748/wjg.v23.i27.4847

[22] Yazici C., Boulay B.R. Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors // World J Gastroenterol. 2017. Vol. 23, No. 27. P. 4847–4855. DOI: 10.3748/wjg.v23.i27.4847

[23] Niederle B, Pape UF, Costa F, et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016;103(2):125–138. DOI: 10.1159/000443170

[24] Niederle B., Pape U.F., Costa F., et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum // Neuroendocrinology. 2016, Vol. 103, No. 2. P. 125–138. DOI: 10.1159/000443170

[25] Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther. 2018;18(9):837–860. DOI: 10.1080/14737140.2018.1496822

[26] Lee L., Ito T., Jensen R.T. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies // Expert Rev Anticancer Ther. 2018. Vol. 18, No. 9. P. 837–860. DOI: 10.1080/14737140.2018.1496822

[27] Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105(3):212–244. DOI: 10.1159/000471879

[28] Sundin A., Arnold R., Baudin E., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging // Neuroendocrinology. 2017. Vol. 105, No. 3. P. 212–244. DOI: 10.1159/000471879

[29] Deroose CM, Hindié E, Kebebew E, et al. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. J Nucl Med. 2016;57(12):1949–1956. DOI: 10.2967/jnumed.116.179234

[30] Deroose C.M., Hindié E., Kebebew E., et al. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions // J Nucl Med. 2016;57(12):1949–1956. DOI: 10.2967/jnumed.116.179234

[31] Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1786. DOI: 10.1038/s41379-018-0110-y

[32] Rindi G., Klimstra D.S., Abedi-Ardekani B., et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal // Mod Pathol. 2018. Vol. 31, No. 12. P. 1770–1786. DOI: 10.1038/s41379-018-0110-y

[33] Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–196. DOI: 10.1097/SLA.0b013e3181b13ca2

[34] Clavien P.A., Barkun J., de Oliveira M.L., et al. The Clavien-Dindo classification of surgical complications: five-year experience // Ann Surg. 2009. Vol. 250, No. 2. P. 187–196. DOI: 10.1097/SLA.0b013e3181b13ca2

[35] Petri A, Sebin K. Naglyadnaya medicinskaya statistika. 3-e izd., dop.; per. s angl. Ed. VP. Leonova. Moscow: Geotar-Media; 2019. P. 216. (In Russ.).

[36] Петри А., Сэбин К. Наглядная медицинская статистика. — 3-е изд., доп.; пер. с англ. / под ред. В.П. Леонова. М.: Гэотар-Медиа. 2019. 216 с.

[37] Rebrova OYu. Statistical analysis of medical data. Application of the Statistica application software package. Moscow: MediaSfera; 2002. P. 312. (In Russ.).

[38] Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ Statistica. М.: МедиаСфера. 2002. 312 с.

[39] Kamp K, Damhuis RA, Feelders RA, et al. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocr Relat Cancer. 2012;19(1):95–99. DOI: 10.1530/ERC-11-0315

[40] Kamp K., Damhuis R.A., Feelders R.A., et al. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas // Endocr Relat Cancer. 2012. Vol. 19, No. 1. P. 95–99. DOI: 10.1530/ERC-11-0315

[41] Kauffmann RM, Wang L, Phillips S, et al. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. Ann Surg Oncol. 2014;21(11):3422–3428. DOI: 10.1245/s10434-014-3774-7

[42] Kauffmann R.M., Wang L., Phillips S., et al. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors // Ann Surg Oncol. 2014. Vol. 21, No. 11. P. 3422–3428. DOI: 10.1245/s10434-014-3774-7

[43] Di Giacinto P, Rota F, Rizza L, et al. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. Int J Endocrinol. 2018;2018:8126087. DOI: 10.1155/2018/8126087

[44] Di Giacinto P., Rota F., Rizza L., et al. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors // Int J Endocrinol. 2018. Vol. 2018. P. 8126087. DOI: 10.1155/2018/8126087

[45] Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016;30(1):59–77. DOI: 10.1016/j.beem.2016.01.002

[46] Modlin I.M., Bodei L., Kidd M. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms // Best Pract Res Clin Endocrinol Metab. 2016. Vol. 30, No. 1. P. 59–77. DOI: 10.1016/j.beem.2016.01.002

[47] Mehrabi A, Fischer L, Hafezi M, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675–686. DOI: 10.1097/MPA.0000000000000110

[48] Mehrabi A., Fischer L., Hafezi M., et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma // Pancreas. 2014. Vol. 43, No. 5. P. 675–686. DOI: 10.1097/MPA.0000000000000110

[49] Canellas R, Burk KS, Parakh A, et al. Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. AJR Am J Roentgenol. 2018;210(2):341–346. DOI: 10.2214/AJR.17.18417

[50] Canellas R., Burk K.S., Parakh A., et al. Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis // AJR Am J Roentgenol. 2018. Vol. 210, No. 2. P. 341–346. DOI: 10.2214/AJR.17.18417

[51] Bochtler T, Löffler H, Krämer A. Diagnosis and management of metastatic neoplasms with unknown primary. Semin Diagn Pathol. 2018;35(3):199–206. DOI: 10.1053/j.semdp.2017.11.013

[52] Bochtler T., Löffler H., Krämer A. Diagnosis and management of metastatic neoplasms with unknown primary // Semin Diagn Pathol. 2018. Vol. 35, No. 3. P. 199–206. DOI: 10.1053/j.semdp.2017.11.013

[53] Romashchenko PN, Majstrenko NA, Orlova RV, Lysanyuk MV. Possibilities of treating patients with generalized neuroendocrine tumors. PA. Herzen Journal of Oncology. 2018;7(2):16–25. (In Russ.). DOI: 10.17116/onkolog20187216-25

[54] Ромащенко П.Н., Майстренко Н.А., Орлова Р.В., Лысанюк М.В. Возможности лечения больных генерализованными нейроэндокринными опухолями // Онкология. Журнал им. П.А. Герцена. 2018. Т. 7, № 2. С. 16–25. DOI: 10.17116/onkolog20187216-25

[55] Yang Z, Klimstra DS, Hruban RH, et al. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver. Am J Surg Pathol. 2017;41(7):915–922. DOI: 10.1097/PAS.0000000000000876

[56] Yang Z., Klimstra D.S., Hruban R.H., et al. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver // Am J Surg Pathol. 2017. Vol. 41, No. 7. P. 915–922. DOI: 10.1097/PAS.0000000000000876

[57] Sallinen V, Le Large TY, Galeev S, et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors — a systematic review and meta-analysis. HPB (Oxford). 2017;19(4):310–320. DOI: 10.1016/j.hpb.2016.12.010

[58] Sallinen V., Le Large T.Y., Galeev S., et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors — a systematic review and meta-analysis // HPB (Oxford). 2017. Vol. 19, No. 4. P. 310–320. DOI: 10.1016/j.hpb.2016.12.010

[59] Lysanyuk MV, Romashchenko PN, Majstrenko NA. Features of diagnostics and surgical treatment of patients with neuroendocrine tumors of the small intestine. Tavricheskij Mediko-Biologicheskij Vestnik. 2020;23(2):100–109. (In Russ.). DOI: 10.37279/2070-8092-2020-23-2-100-109

[60] Лысанюк М.В., Ромащенко П.Н., Майстренко Н.А. Особенности диагностики и хирургического лечения больных нейроэндокринными опухолями тонкой кишки // Таврический медико-биологический вестник. 2020. Т. 23, № 2. С. 100–109. DOI: 10.37279/2070-8092-2020-23-2-100-109

[61] Patent RF na izobretenie № 2742747 ot 10.02.2021 g. Romaschenko P.N. Maistrenko N.A. Lisanyuk M.V. Sposob rezekcii tonkoi kishki pri mestnorasprostranennih neiroendokrinnih opuholyah s invaziei verhnih brijeechnih sosudov. Rejim dostupa https//findpatent.ru/patent/274/2742747.html Data obrascheniya: 08.07.21. Patent RUS № 2742747 от 10.02.2021.

[62] Патент РФ на изобретение № 2742747 от 10.02.2021 г. Ромащенко П.Н., Майстренко Н.А., Лысанюк М.В. Способ резекции тонкой кишки при местнораспространенных нейроэндокринных опухолях с инвазией верхних брыжеечных сосудов. Режим доступа: https://findpatent.ru/patent/274/2742747.html Дата обращения: 08.07.21. Patent RUS № 2742747 от 10.02.2021.

[63] Romashchenko PN, Majstrenko NA, Orlova RV, et al. Prediction of treatment outcomes gastroenteropancreatic neuroendocrine tumors. Medical Academic Journal. 2017;17(1):54–66. (In Russ.). DOI: 10.17816/MAJ17254-66

[64] Ромащенко П.Н., Майстренко Н.А., Орлова Р.В. и др. Прогнозирование исходов лечения гастроэнтеропанкреатических нейроэндокринных опухолей // Медицинский академический журнал. 2017. Т. 17, № 1. С. 54–66.

RIGHTS & PERMISSIONS

Lysanyuk M.V., Romashchenko P.N., Maistrenko N.A.